CONSTELLATION TECHNOLOGIES LIMITED — Board/Management Information 2013

May 20, 2013

==> picture [99 x 86] intentionally omitted <==

ASX Announcement

Appointment of Non- Executive Director

MELBOURNE, Australia 21 May 2013: Agenix is pleased to announce the appointment of Mr Craig Chapman as a non-executive Director with immediate effect.

Craig has over 25 years experience across a range of service sectors and has been instrumental in a number of highly successful consolidation plays listed on the ASX including S8 (SEL), Greencross (GXL) and G8 Education (GEM).

Craig has held senior management roles, company secretarial positions and directorships with the above companies.

Craig holds a Bachelor of Commerce degree from the University of Queensland and is a CPA. He also holds a Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Secretaries and Administrators.

In announcing the appointment, Agenix Executive Chairman, Nick Weston said “Craig’s experience in financial markets, management and his professional background will further strengthen our board’s focus on the bottom line and complement our existing expertise”.

Agenix is commercialising a revolutionary blood clot diagnostic called ThromboView, a human health point of care diagnostic platform called DiagnostIQ and a hepatitis B therapy for China.

For more information please contact:

Nicholas Weston

Agenix Limited

Tel: 1300 132 551

® ThromboView is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited.

Agenix Limited 156 Collins Street, Melbourne, Victoria 3000 Australia Tel: 1300 132 551 ABN 58 009 213 754 www.agenix.com

About Agenix

Agenix has taken successfully from laboratory to global commercialisation then commercial exit more than 20 products over four technology platforms since listing on the Australian Securities Exchange in 1987. Today, Agenix is focused on the commercialisation of innovative monoclonal antibody blood clot diagnostics, rapid point of need diagnostics and small molecule drugs for the treatment of hepatitis B and other serious diseases. Agenix’s most advanced diagnostic candidate, ThromboView®, a novel radio-labelled monoclonal antibody imaging agent, has completed two Phase 2 clinical trials, and is ideal to diagnose patients indicated for suspected acute pulmonary embolism (PE), with a positive D-dimer blood test or moderate to high pre-test probability of PE, as a replacement diagnostic test for patients with suspected PE where V/Q scans are a first line choice and are unlikely to deliver a diagnostic result, as a confirmatory diagnostic where CT is used as a first-line diagnostic test, the scan result is negative and the clinical probability of disease is high or moderate and as a replacement diagnostic where CTPA is an inappropriate choice based on radiation exposure, renal impairment or contrast allergy.

Agenix’s human health diagnostics platform, DiagnostIQ® is a patented disposable test device for use with multiple sample types at point-of-care. DiagnostIQ® utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a vertical flow through format to create a sensitive and quantitative, rapid, multi-analyte test. The patented technology provides the potential for point-of-need testing that is simple and quick to use, gives rapid and accurate results.

Agenix is also developing AGX 1009, a next-generation reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a CTA is planned to be filed with the Chinese FDA in 2Q 2013 and is currently engaging with potential partners to advance into the clinic. Agenix owns all the patent rights to both ThromboView® and AGX 1009. In August 2010, Agenix entered into a collaborative partnership with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences, part of the Ministry of Health to purchase AGX 1009 and preclinical work is being completed in Beijing, China by the Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences.

Agenix Limited 156 Collins Street, Melbourne, Victoria 3000 Australia Tel: 1300 132 551 ABN 58 009 213 754 www.agenix.com